

ANNA-MARIA FONTRIER

London School of Economics • Cowdray House • London WC2A 2AE
A.Fontrier@lse.ac.uk • +44 7736151554

EMPLOYMENT

- 2018- Present Senior Researcher (full time), London School of Economics and Political Science
- 2015- 2018 Researcher (full time), London School of Economics and Political Science
- 2014-2015 Junior Expert for Healthcare Reform Support Programme implementation, Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH
- 2010-2011 Marketing Trainee, Novartis Hellas

MAIN PROJECTS

- 2020-2021 Access to medicines in Europe, underlying reasons for access barriers and recommendations for improving access to new therapies: Merck Sharp & Dohme (MSD)
- 2020-2021 Development of policies to increase headroom for innovation in Egypt and Saudi Arabia: Pharmaceutical Research and Manufacturers of America (PhRMA)
- 20019-2020 HTA policy toolkit- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- 2019 HTA in Middle Income Countries (MIC)- World Health Organization
- 2018-2019 IMPACT HTA – European Commission project (Horizon 2020)
- 2017-2018 Pricing and reimbursement in the Middle East and North Africa region- Pharmaceutical Research and Manufacturers of America (PhRMA)
- 2016-2018 Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) – European Commission
- 2015-2017 External Reference Pricing within and across countries- Pfizer

OTHER PROJECTS

My team and myself have been involved in numerous other projects, including medium and small-scale projects in close collaboration with country governments, big pharmaceutical companies, in England, Switzerland and Greece as well as other consulting firms. These projects have been focused on Health Technology Assessment (HTA), pricing and reimbursement policies for pharmaceuticals.

EDUCATION

- Present Ph.D. Department of Health Policy
Topic title: Impact of HTA recommendations in coverage decisions: Predictors of HTA outcomes in Europe, Australia and Canada
London School of Economics
- 2014 M.Sc. in International Health Policy
London School of Economics and Political Science – Department of social policy
- 2012 B.Sc. Business Administration and Chemistry
Aston University

PUBLICATIONS

PEER-REVIEWED ARTICLES

- Fontrier, A.M., Gill, J. and Kanavos, P., 2019. International impact of external reference pricing: should national policy-makers care?. *The European Journal of Health Economics*, 20(8), pp.1147-1164.
- Kanavos, P., Fontrier, A.M., Gill, J. and Efthymiadou, O., 2020. Does external reference pricing deliver what it promises? Evidence on its impact at national level. *The European Journal of Health Economics*, 21(1), pp.129-151.
- Gill, J., Fontrier, A.M., Kyriopoulos, D. and Kanavos, P., 2019. Variations in external reference pricing implementation: does it matter for public policy?. *The European Journal of Health Economics*, 20(9), pp.1375-1397.
- Kanavos, P, Tzouma,V, Fontrier, A.M., Souliotis, K. 2019. “Implementing health technology assessment (HTA) in Greece.” *Athens Medical Society. Archives of Hellenic Medicine* 36,(4) pp 444-451.
- Kanavos, P., Kamphuis, B., Fontrier, A.M., Colville, G., Saleh, S. and Akhras, K.S., 2020. Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?. *Health Policy*.

IN PROGRESS

- Frontier A.M, Visintin E, Kanavos PG. " HTA systems across Europe, United Kingdom, Canada and Australia: A mapping exercise of the key similarities and differences" (Under review)
- Fontrier A.M. "Do specialised regulatory and assessment pathways for orphan drugs have an impact on timely access and reimbursement recommendations? A comparison study in Scotland and Canada."
- Fontrier, A.M and Kanavos, P. "Orphan designation as a predictor of positive HTA recommendations at funding level in Scotland and Canada"
- Visintin E, Frontier A.M, Kanavos PG. " Retrospective analysis of HTA decision across different health technologies: A comparison of pharmaceuticals, medical devices and other technologies assessment ".
- Frontier A.M, Visintin E, Kanavos PG, "Prescribing appropriateness in the management of Rheumatoid Arthritis using biologic or non-biologic agents in US healthcare settings: A systematic literature review".

SELECTED REPORTS

- Habl, C., Laschkolnig, A., Habimana, K., Stürzlinger, H., Röhring, I., Bobek, J., Kanavos, P., Visintin, E., Fontrier, A.M. and Mills, M., 2017. "Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA)".
- Kanavos, P., Fontrier, A.M., Gill, J., Efthymiadou, O. and Boekstein, N., 2017. "The impact of external reference pricing within and across countries".
- Kanavos, P., Tzouma, V., Fontrier, A.M., Kamphuis, B., Parkin, G.C. and Saleh, S., 2018. "Pharmaceutical pricing and reimbursement in the Middle East and North Africa region".
- Kanavos, P., Tzouma, V., Fontrier, A.M., 2018. "HTA Implementation in Greece"
- Kanavos, P., Tzouma, V., Fontrier, A.M., 2020. "Opportunities and obstacles in diabetes policy in Greece: An Expert Consultation to lay the foundations for an all-important reform".

SELECTED PRESENTATIONS & POSTERS

- Fontrier, A.M., Gill, J, Kanavos P, The impact of external reference pricing within and across borders. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Wien, Austria, 2016.

LANGUAGE & IT SKILLS

Languages: Fluent in English and Greek and working knowledge of French.

Software Programs: Qualtrics, Stata, EndNote

JOURNAL REVIEWER

Peer Reviewer (Journals): Health Policy and European Journal of Health Economics

UPDATED: September 2021